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Sir—We read with great interest the article by
Ramsey and colleagues [1]. In their study, they
concluded that imiquimod had no efﬁcacy in
controlling Chlamydia trachomatis MoPn (mouse
pneumonitis agent) infection in a murine model of
female genital tract infection. Imiquimod is an
immune response modiﬁer that induces the produc-
tion of an array of essentially Th1 response
promoting cytokines, most notably tumor necrosis
factor-alpha and interferon-gamma, the pluripotent
cytokine that is considered essential in both the
innate and the acquired immune response to C.
trachomatis genital tract infection.
We, as well as others, have shown that the course
of female genital tract infection with MoPn in IFN-
gamma knockout mice is only minimally different
when compared with genetically intact mice,
whereas infection with a human isolate of C.
trachomatis serovar D is uncontrolled during the
acute phase and of signiﬁcantly longer duration in
interferon-gamma deﬁcient mice [2, 3]. Therefore,
we investigated the effect of various regimens of
vaginally applied imiquimod on the course of
infection in essentially the same murine model of
C. trachomatis female genital tract infection as used
by Ramsey and colleagues, but employing a strain
belonging to the human oculogenital biovar of C.
trachomatis.
In brief, CF-1 mice treated with progesterone were
inoculated intravaginally by direct instillation of
10 ml of bacterial suspension containing 1 X 105
inclusion-forming units (ifu) of C. trachomatis
serovar D [4]. On the days before (7) and after
( + ) infection as indicated in the results table, 10 ml
of imiquimod (AldaraTM), diluted 1:4 in saline or a
placebo similar in composition to the inactive base
used in the imiquimod preparation, was adminis-
tered intravaginally [5]. The presence of Chlamydia
in the lower genital tract was determined by culturing
the vaginal contents as previously described, and the
duration of infection between groups was analyzed
using the Wilcoxon rank sum test [2, 4, 5].
As displayed below, we observed a statistically
signiﬁcant reduction in the median duration of
infection in mice treated prophylactically with
imiquimod several times before and during the acute
phase of C. trachomatis infection, i.e. 4 days for
treated animals compared with 19 days for the group
receiving placebo. No effect on the course of
infection was seen with other regimens, a single
application 2 h before or multiple applications every
other day beginning 4 days after chlamydial inocula-
tion and ending on day 14 (data not shown).
Remarkably, in the prophylactically treated group
on day 2, no effect was observed on the incidence of
infection when compared with the placebo group.
However, by day 4 differences between the groups
were apparent, implying that treated mice were
primed to respond more rapidly to infection, while
apparently unaltered in their susceptibility to initial
infection. In mice, imiquimod is reported to act
through the Toll-like receptor 7 (TLR7) MyD88-
dependent signalling pathway This suggests that, in
contrast to the speculation of Ramsey and collea-
gues, sufﬁcient quantities of the TLR7 are expressed
in the mouse genital epithelium or in tissues adjacent
to the genital epithelium to allow a response to
imiquimod.
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The signiﬁcant difference between our results and
the results of Ramsey and colleagues may be a result
of the genetic background of the mouse strains
involveded (BALB/c versus CF-1), the slightly
different prophylactic regimens tested, or, as our
previous studies suggest, the strain of C. trachomatis
used in the setting of the murine female genital tract
(MoPn versus human urogenital isolates such as
serovar D). With regard to the latter, and based on
published differences between these two biovars of
Chlamydia, we have recently suggested that the use of
human urogenital isolates may be more appropriate
in certain types of experiments in which these
differences could affect the translational value of
the results obtained [6].
In conclusion, in the much used murine model of
the human female genital tract infection and in
contrast to the results of Ramsey and colleagues, we
observed that imiquimod intravaginally applied
prophylactically on multiple occasions, days before
infection, may enhance local natural immunity and
shorten the duration of genital tract infection with a
human isolate of C. trachomatis, perhaps through a
mechanism of enhanced local natural immunity.
Understanding the mechanism of this enhanced
responsiveness might provide insight into the com-
plex immunobiology of female genital tract infection
with C. trachomatis and may lead to new prevention
and treatment methods. In this context, it is
interesting to speculate if women using the multiple
application regimen of imiquimod approved for the
treatment of genital warts might realize an alteration
in the cytokine responsiveness within the genital tract
and a possible reduced risk of C. trachomatis genital
tract infection.
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